Literature DB >> 29220700

Prognostic importance of Aurora Kinases and mitotic spindle genes transcript levels in Myelodysplastic syndrome.

Daniela de Paula Borges1, Antônio Wesley Araújo Dos Santos2, Carlos Roberto Koscky Paier3, Howard Lopes Ribeiro1, Marília Braga Costa1, Izabelle Rocha Farias1, Roberta Taiane Germano de Oliveira1, Ivo Gabriel da Frota França2, Gabrielle Melo Cavalcante2, Sílvia Maria Meira Magalhães1, Ronald Feitosa Pinheiro4.   

Abstract

Myelodysplastic syndrome (MDS) are a heterogeneous group of clonal disease characterized by insufficiency of bone marrow, increase of apoptosis and increased risk of acute leukemia progression. Proteins related to the mitotic spindle (AURKA, AURKB, TPX2), to the mitotic checkpoint (MAD2, CDC20) and the regulation of the cell cycle (p21) are directly related to chromosomal stability and tumor development. This study aimed to evaluate the mRNA expression levels of these genes in 101 MDS patients using a real-time PCR methodology. We identified that CDC20 expression are increased in patients with dysmegakaryopoiesis (p=0.024), thrombocytopenia (p=0.000) and high-risk patients (p=0.014, 0.018) MAD2 expression are decreased in patients with 2 or 3 cytopenias (p=0.000) and neutrophil below 800/mm3. TPX2 is also overexpressed in patients presenting dysmegakaryopoiesis (p=0.009). A decrease in AURKA and AURKB expression were observed in patients with altered karyotype (p=0.000), who presented dysplasia in 3 lineages (p=0.000; 0.017) and hemoglobin inferior to 8g/dL (p=0.024). The expression of AURKA, AURKB and MAD2 (p=0.000; 0.001; 0.025) were decreased in patients with hypoplastic MDS, associated with high frequency of chromosomal alterations and high mortality rate. This study reaffirms the importance of aurora kinases and mitotic spindle genes to the pathogenesis and clinical evolution of MDS.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer biology; Cell cycle; Mitotic checkpoint; Mitotic spindle; Myelodysplastic syndrome

Mesh:

Substances:

Year:  2017        PMID: 29220700     DOI: 10.1016/j.leukres.2017.11.013

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

1.  Global Proteomics Analysis of Bone Marrow: Establishing Talin-1 and Centrosomal Protein of 55 kDa as Potential Molecular Signatures for Myelodysplastic Syndromes.

Authors:  Arlindo A Moura; Maria Julia B Bezerra; Aline M A Martins; Daniela P Borges; Roberta T G Oliveira; Raphaela M Oliveira; Kaio M Farias; Arabela G Viana; Guilherme G C Carvalho; Carlos R K Paier; Marcelo V Sousa; Wagner Fontes; Carlos A O Ricart; Maria Elisabete A Moraes; Silvia M M Magalhães; Cristiana L M Furtado; Manoel O Moraes-Filho; Claudia Pessoa; Ronald F Pinheiro
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

Review 2.  Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy.

Authors:  Alex Aleshin; Peter L Greenberg
Journal:  Blood Adv       Date:  2018-10-23

3.  Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia.

Authors:  Caroline Aquino Moreira-Nunes; Felipe Pantoja Mesquita; Adrhyann Jullyanne de Sousa Portilho; Fernando Augusto Rodrigues Mello Júnior; Jersey Heitor da Silva Maués; Laudreísa da Costa Pantoja; Alayde Vieira Wanderley; André Salim Khayat; William J Zuercher; Raquel Carvalho Montenegro; Manoel Odorico de Moraes-Filho; Maria Elisabete Amaral de Moraes
Journal:  Sci Rep       Date:  2020-12-04       Impact factor: 4.379

Review 4.  Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?

Authors:  Bruno Fattizzo; Fabio Serpenti; Wilma Barcellini; Chiara Caprioli
Journal:  Cancers (Basel)       Date:  2021-01-03       Impact factor: 6.639

5.  Mitotic Errors Promote Genomic Instability and Leukemia in a Novel Mouse Model of Fanconi Anemia.

Authors:  Donna M Edwards; Dana K Mitchell; Zahi Abdul-Sater; Ka-Kui Chan; Zejin Sun; Aditya Sheth; Ying He; Li Jiang; Jin Yuan; Richa Sharma; Magdalena Czader; Pei-Ju Chin; Yie Liu; Guillermo de Cárcer; Grzegorz Nalepa; Hal E Broxmeyer; D Wade Clapp; Elizabeth A Sierra Potchanant
Journal:  Front Oncol       Date:  2021-11-05       Impact factor: 5.738

Review 6.  CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies.

Authors:  Samantha Bruno; Andrea Ghelli Luserna di Rorà; Roberta Napolitano; Simona Soverini; Giovanni Martinelli; Giorgia Simonetti
Journal:  J Exp Clin Cancer Res       Date:  2022-04-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.